⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Boston Scientific removed its COVID-19 pandemic risk disclosure from its 2024 10-K, reflecting a transition away from treating pandemic-related disruptions as a material ongoing concern. The company substantively modified three risk factors, including those addressing healthcare industry consolidation and pricing pressures, as well as acquisition integration challenges. With 23 risks remaining unchanged and no new risks added, the company's overall risk profile remained relatively stable year-over-year.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🔴 No Match in Current Filing The global COVID-19 pandemic and related impacts have had, and could in the future have, an adverse effect on our operations, financial performance and cash flows. We are unable to predict the extent to which the pandemic or a similar health crisis and related impacts may adversely impact our business operations, financial performance, results of operations, financial position and the achievement of our strategic objectives. 🔒

🟡 Modified Continued consolidation in the health care industry or additional governmental controls exerted over pricing and access in key markets could lead to increased demands for price concessions or limit or eliminate our ability to sell to certain of our significant market segments, which could have an adverse effect on our business, financial condition or results of operations. 🔒

🟡 Modified Failure to integrate acquired businesses into our operations successfully could adversely affect our business, financial condition and operating results. 🔒

🟡 Modified Health care policy changes may have a material adverse effect on our business, financial condition, results of operations and cash flows. 🔒

4 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →